Bevacizumab in Combination with Capecitabine/Irinotecan or Capecitabine/Oxaliplatin is Effective and Safe as First-Line Therapy for Metastatic Colorectal Cancer: a Randomized Phase II Study of the Aio Colorectal Study Group

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Aug 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Capecitabine; Irinotecan; Oxaliplatin
Indications Colorectal cancer
Focus Therapeutic Use

Most Recent Events

09 Nov 2010 New trial record
27 Oct 2010 Results were presented at the 18th United European Gastroenterology Week.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight